π§π΅πΆπ»πΈππΌππ. The Biogen/Eisai investigational Alzheimer's monoclonal antibody lecanemab achieved its main endpoint in a large clinical trial. With the FDA planning to review it in early January 2023, what will this drug mean for the treatment of Alzheimerβs disease?
Read more about this here: https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-says-alzheimers-drug-succeeds-slowing-cognitive-decline-2022-09-27/